Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3799408
Max Phase: Preclinical
Molecular Formula: C52H71N13O11
Molecular Weight: 1054.22
Molecule Type: Small molecule
Associated Items:
ID: ALA3799408
Max Phase: Preclinical
Molecular Formula: C52H71N13O11
Molecular Weight: 1054.22
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O
Standard InChI: InChI=1S/C52H71N13O11/c1-34(66)62-45(28-39-30-56-33-61-39)51(72)64-43(26-35-14-15-36-9-2-3-10-37(36)25-35)50(71)63-42(13-6-16-59-52(54)55)49(70)65-44(27-38-29-60-41-12-5-4-11-40(38)41)48(69)58-18-8-20-74-22-24-75-23-21-73-19-7-17-57-47(68)32-76-31-46(53)67/h2-5,9-12,14-15,25,29-30,33,42-45,60H,6-8,13,16-24,26-28,31-32H2,1H3,(H2,53,67)(H,56,61)(H,57,68)(H,58,69)(H,62,66)(H,63,71)(H,64,72)(H,65,70)(H4,54,55,59)/t42-,43+,44-,45-/m0/s1
Standard InChI Key: RXENDXVKKZXQPW-CSYVQODNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1054.22 | Molecular Weight (Monoisotopic): 1053.5396 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Lensing CJ, Freeman KT, Schnell SM, Adank DN, Speth RC, Haskell-Luevano C.. (2016) An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers., 59 (7): [PMID:26959173] [10.1021/acs.jmedchem.5b01894] |
2. Lensing CJ, Freeman KT, Schnell SM, Speth RC, Zarth AT, Haskell-Luevano C.. (2018) Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors., 62 (1): [PMID:29669202] [10.1021/acs.jmedchem.8b00238] |
Source(1):